CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 192 enrolled
Drug / intervention
Genicular Nerve Block with bupivacaine and preservative free dexamethasonedrug
Likely dose
Genicular Nerve Block with bupivacaine and preservative free dexamethasone 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05720949
NCT05720949Phase 4Completed

Genicular Nerve Blocks for Arthroscopic Anterior Cruciate Knee Surgery: a Randomized Controlled Trial

Hospital for Special Surgery, New York·interventional·Posted Feb 9, 2023·Updated Jan 26, 2026

In Brief

A Phase 4 clinical trial evaluating Genicular Nerve Block with bupivacaine and preservative free dexamethasone for ACL and Anterior Cruciate Ligament Injuries. Completed, enrolled 192 participants across 1 site.

Detailed Summary

The purpose of this randomized controlled trial is to assess a new analgesia regimen that includes the addition of genicular never blocks to our current standard regimen of peripheral nerve blocks, which includes an adductor canal block (ACB) and interspace between the popliteal artery and capsule of the posterior knee block (IPACK). The main questions it aims to answer are: 1. Does addition of genicular nerve blocks to standard peripheral block regimen significantly reduce the mean opioid consumption by 33% in the first 24 hours? 2. Does genicular nerve blocks reduce NRS pain scores? 3. Does genicular nerve blocks facilitate earlier discharge? 4. Does genicular nerve blocks last longer than 24 hours? 5. Does genicular nerve blocks improve pain management? Eligible patients are those undergoing an anterior cruciate ligament repair at the Hospital for Special Surgery and participants will be randomized to receive the intervention (genicular nerve block) or the standard of care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedFeb 9, 2023
Enrollment StartJan 12, 2023
Primary CompletionNov 26, 2024
Study CompletionDec 2, 2024
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 3.4 years ago

Interventions

Genicular Nerve Block with bupivacaine and preservative free dexamethasonedrug

A genicular nerve block is a peripheral nerve block that temporarily anesthetizes the sensory terminal branches innervating the knee joint by injecting local anesthesia. This results in anesthesia of the anterior compartment of the knee. The genicular nerve block consists of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone and will be applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius. Bupivacaine - Drug class: Sodium channel blocker Dexamethasone - Drug class: Glucocorticoid